Orexo AB
ORX
Rank in Stocks
#31173
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Share Price
$0.09638049
Last synced: 2026-11-20
Market Cap
$3.39M
Change (1 day)
-1.97%
Change (1 year)
-96.53%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Orexo AB (ORX)
Category
Healthcare
EPS for Orexo AB (ORX)
EPS as of September 2026 TTM: $-1.06
According to Orexo AB's latest financial reports, its current EPS (TTM) is $-1.06. At the end of 2025 the company had an EPS of $-0.41, an increase over its 2024 EPS of $-0.53.
EPS history for Orexo AB from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.06 | 158.78% |
| 2025 | $-0.41 | -23.90% |
| 2024 | $-0.53 | 44.44% |
| 2023 | $-0.37 | -25.43% |
| 2022 | $-0.50 | -31.07% |
| 2021 | $-0.72 | 142.60% |
| 2020 | $-0.30 | -143.73% |
| 2019 | $0.68 | 51.84% |
| 2018 | $0.45 | 445.30% |
| 2017 | $0.08 | -11.46% |
| 2016 | $0.09 | -113.59% |
| 2015 | $-0.68 | 206.95% |
| 2014 | $-0.22 | -72.33% |
| 2013 | $-0.80 | 78.52% |
| 2012 | $-0.45 | -78.58% |
| 2011 | $-2.10 | 269.04% |
| 2010 | $-0.57 | -6.21% |
| 2009 | $-0.61 | -0.31% |
| 2008 | $-0.61 | -65.77% |
| 2007 | $-1.77 | 394.29% |
| 2006 | $-0.36 | -12.42% |
| 2005 | $-0.41 | -99.40% |
| 2004 | $-67.91 | -50.21% |
| 2003 | $-136.39 | 42.97% |
| 2002 | $-95.39 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | -259.28% |
US
|
|
| $1.90 | -278.96% |
SE
|
|
| $6.83 | -744.17% |
FR
|
|
| $0.02 | -101.84% |
HK
|
|
| $2.81 | -364.94% |
IT
|
Questions about Orexo AB's earnings per share (EPS)
What is Orexo AB's earnings per share (EPS)?
Orexo AB's earnings per share (EPS) over the last twelve months is $-1.06, as of Sep 2026.
What was Orexo AB's earnings per share (EPS) in 2025?
In 2025, Orexo AB's earnings per share (EPS) was $-0.41, compared with $-0.53 in 2024.
How has Orexo AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Orexo AB's earnings per share (EPS) was highest in 2020 ($-0.30) and lowest in 2021 ($-0.72).
How does Orexo AB's earnings per share (EPS) compare with similar companies?
Orexo AB's earnings per share (EPS) ($-1.06) is lower than that of all 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.83.